GPBAR1 and metabolic disease: Phillips et al. carried out extensive lead optimization from a high-throughput screen hit and ultimately determined that compound 45 h (trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides) was a potent and selective GPBAR1 agonist that plays an effective role in clinical metabolic diseases (Phillips et al., 2014).